Aminocaproic acid interactions
Full monograph for Aminocaproic acidCheck it against another medicine
Medicines
145 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Carfilzomib | Major | Synergy | Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent… | 3 sources — open the full entry |
| Clindamycin + Tretinoin | Major | Synergy | Coadministration of tretinoin (all-trans retinoic acid) with antifibrinolytic agents may increase the risk of thrombosis. Tretinoin is associated with a risk… | 3 sources — open the full entry |
| Fluocinolone Acetonide + Hydroquinone + Tretinoin | Major | Synergy | Coadministration of tretinoin (all-trans retinoic acid) with antifibrinolytic agents may increase the risk of thrombosis. Tretinoin is associated with a risk… | 3 sources — open the full entry |
| Tretinoin (Oral) | Major | Synergy | Coadministration of tretinoin (all-trans retinoic acid) with antifibrinolytic agents may increase the risk of thrombosis. Tretinoin is associated with a risk… | 3 sources — open the full entry |
| Alteplase | Moderate | Antagonism | Coadministration of an antifibrinolytic agent (e.g., aminocaproic acid, tranexamic acid, aprotinin) in combination with a tissue plasminogen activator (t-PA)… | 4 sources — open the full entry |
| Streptokinase | Moderate | Antagonism | Coadministration of an antifibrinolytic agent (e.g., aminocaproic acid, tranexamic acid, aprotinin) in combination with a tissue plasminogen activator (t-PA)… | 4 sources — open the full entry |
| Tenecteplase | Moderate | Antagonism | Coadministration of an antifibrinolytic agent (e.g., aminocaproic acid, tranexamic acid, aprotinin) in combination with a tissue plasminogen activator (t-PA)… | 4 sources — open the full entry |
| Ticagrelor | Minor | Antagonism | Antifibrinolytic agents (e.g., aminocaproic acid or tranexamic acid) and recombinant factor VIIa may increase hemostasis and antagonize the effects of… | 2 sources — open the full entry |
Conditions
Conditions in which Aminocaproic acid needs care, as documented in this source.
Disseminated Intravascular Coagulation
MajorThe use of aminocaproic acid is contraindicated in patients with active intravascular clotting. Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin. Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis. Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.
1 source
- "Product Information. Amicar (aminocaproic acid)." Immunex Corporation (2001):
Kidney Diseases
MajorAminocaproic acid is primarily eliminated by the kidney. Approximately 65% of aminocaproic acid is excreted unchanged in the urine. Serum concentrations of aminocaproic acid can be increased in patients with renal impairment. Therapy with aminocaproic acid should be administered with extreme caution in patients with upper urinary tract bleeding. Glomerular capillary thrombosis or clots in the renal pelvis and ureters have occurred in patients with upper urinary tract bleeding during aminocaproic acid therapy. Clinical monitoring of renal function, clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.
1 source
- "Product Information. Amicar (aminocaproic acid)." Immunex Corporation (2001):
Muscular Diseases
MajorSkeletal muscle toxicity ranging from mild myalgia to rhabdomyolysis has been reported rarely during prolonged administration of aminocaproic acid. Therapy with aminocaproic acid should be administered cautiously in patients with or predisposed to myopathy. Clinical monitoring of muscle enzymes (particularly CPK) are recommended.
1 source
- "Product Information. Amicar (aminocaproic acid)." Immunex Corporation (2001):